Drug intelligence / Profile preview

Fengye Kechuangping

Development stage: Phase 3
Lead developer: Suzhou Yusen New Drug Development
Administration: Oral

Overview

Fengye Kechuangping is a traditional Chinese medicine (TCM) compound oral solution developed by Suzhou Yusen New Drug Development Co., Ltd. specifically for pediatric use. It is indicated for the treatment of acute bronchitis in children, particularly those presenting with the TCM syndrome of "wind-heat cough" (风热犯肺证). As a TCM formulation, it consists of a mixture of herbal extracts designed to clear heat, ventilate the lungs, and resolve phlegm to alleviate symptoms such as cough and bronchial inflammation. The drug has been evaluated in a randomized, double-blind, parallel-group Phase 2 clinical trial in China (CTR20210397) to assess its efficacy and safety in the pediatric population.

Brand names: Fengye Kechuangping
Other names: Fengye Kechuangping oral solution (pediatric)Fengye Kechuangping oral solution

Beyond the preview

Go deeper on Fengye Kechuangping.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fengye Kechuangping.